Evidence map›Paper›PMID 36700237›Full record

ArticleJournal of pathology informatics2023

Bioinformatics evaluation of anticancer properties of GP63 protein-derived peptides on MMP2 protein of melanoma cancer.

Fatemeh Sharifi, Iraj Sharifi, Zahra Babaei, Sodabeh Alahdin, Ali Afgar

Open access · goldAbstract read
In one paragraph

Article in Journal of pathology informatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Short Fragmented Peptides fromCurrent drug discovery technologies · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Fatemeh SharifiResearch Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
Iraj SharifiLeishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Zahra BabaeiLeishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Sodabeh AlahdinLeishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Ali AfgarResearch Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran.
Kerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: GP63, also known as Leishmanolysin, is a multifunctional virulence factor abundant on the surface of Methods: Various Results: We used 3 peptides of GP63 based on the AntiCP 2.0 server with scores of 0.63, 0.53, and 0.49, and common peptides of GP63/MMP2 (continues peptide: mean the completely selected peptide after docking with non-anticancer effect, predicted with 0.58 score and designed peptides with 0.47 and 0.45 scores by AntiCP 2.0 server). Conclusions: The antileishmanial and anticancer peptide research topics exemplify the multidisciplinary nature of peptide research. The advancement of therapeutics targeting cancer and/or

Indexed as

ACPs, anticancer peptidesAnticancerCASTp, Computed Atlas of Surface Topography of proteinsCL, cutaneous leishmaniasisGP63, Glycoprotein 63In silicokNN, k-Nearest NeighborsLeishmaniaLeishmanolysinMatrix metalloproteasesMD, molecular dynamicsMMPs, matrix metalloproteasesMSP, major surface proteasePDB, Protein Data BankPeptidePLIP, Protein–Ligand Interaction ProfilerProtein–Ligand Interaction ProfilerROS, reactive oxygen species formationSVM, Support Vector MachineVL, visceral leishmaniasis

Identifiers

PMID36700237
PMCPMC9867975
OpenAlexW4315628715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.